Treatment of Asymptomatic Donor Specific Antibody After Heart Transplantation: Is It Beneficial? | Synapse
April 24, 2026
Treatment of Asymptomatic Donor Specific Antibody After Heart Transplantation: Is It Beneficial?
Key Points
This research aims to evaluate the impact of treating asymptomatic donor specific antibodies on heart transplant outcomes.
Randomized trial design
Participants with asymptomatic donor specific antibodies were treated
Clinical outcomes were monitored post-transplant.
Treatment significantly reduced the incidence of graft rejection, with an incidence rate of 12% in the treatment group compared to 25% in the control group (HR 0.48, 95% CI 0.25-0.92, P=0.03).
Improved transplant survival rates were observed at one year, 90% in the treatment group vs. 75% in the control group (HR 0.60, 95% CI 0.40-0.90, P=0.01).